���构特征与受体作用机制 — Explained

By Editorial Desk · published 2025-11-18 · last reviewed 2025-12-15 · Wiki

This is a working overview of GLP-1 analog, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Background and Molecular Profile

The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Semaglutide at a glance

Background and Mechanism of Action

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Related pages on this site

• Gradual primer
• Reliable overview
• Proven update
• Automated report
• Material overview
• Modular dataset
• Regional summary
• Technical guide

Handling, Storage, and Characterization

Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.

Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Peptide Background and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Mechanism and Pharmacological Class

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Supporting material

The conjugate addition between Ethyl crotonate [623-70-1][10544-63-5] (1) and dimethylamine gives Ethyl 3-(Dimethylamino)Butanoate [85118-28-1] (2). Grignard reaction with 2-Bromothiophene [1003-09-4] (3) gives (4). Dehydration in acid completed the synthesis (5).

==== Lower side effects ==== Both photosensitizers and photothermal agents have some degree of selectivity for target cells over healthy human cells, but in utilizing both of these mechanisms this selectivity is bolstered. Increased antibiotic efficacy indicates a lower likelihood of requiring follow-up treatments, so the damage is minimal. In addition, some of these combination phototherapeutic agents have antioxidant/reactive oxygen scavenging properties, reducing the amount of collateral damage sustained by the surrounding human cells.

She commented that reviving memories of a suit that the majority of the public had forgotten after the initial burst of publicity was the wrong strategy from Taco Bell. In March 2012, Taco Bell teamed up with Frito-Lay and created the Doritos Locos Tacos, which is a taco with a Dorito Nacho Cheese flavored taco shell. In May 2012, Taco Bell released a drink named Mountain Dew A.M, a mixture of Mountain Dew and orange juice. On June 6, 2012, Taco Bell announced it would be testing a new "Cantina Menu" with upscale items in their Kentucky and California restaurants. The new menu was created by celebrity chef Lorena Garcia, and featured the addition of: Black Beans; Cilantro Rice; Citrus & Herb Marinated Chicken; and Cilantro Dressing. The Cool Ranch Doritos Taco, became available to order on March 7, 2013. Shortly before its release, Taco Bell launched a promotion advertising that fans could get the new flavor at its stores a day early if they "just asked" on March 6. However, they neglected to inform the majority of their stores of this – leading to numerous complaints on its social media accounts and news sites from disappointed consumers who were unable to obtain the new taco.

Sources: en.wikipedia.org

Notes from published material

The most commonly used synthetic membrane devices (modules) are flat sheets/plates, spiral wounds, and hollow fibers. Flat membranes used in filtration and separation processes can be enhanced with surface patterning, where microscopic structures are introduced to improve performance. These patterns increase surface area, optimize water flow, and reduce fouling, leading to higher permeability and longer membrane lifespan. Research has shown that such modifications can significantly enhance efficiency in water purification, energy applications, and industrial separations. Flat plates are usually constructed as circular thin flat membrane surfaces to be used in dead-end geometry modules. Spiral wounds are constructed from similar flat membranes but in the form of a "pocket" containing two membrane sheets separated by a highly porous support plate. Several such pockets are then wound around a tube to create a tangential flow geometry and to reduce membrane fouling. Hollow fiber modules consist of an assembly of self-supporting fibers with dense skin separation layers, and a more open matrix helping to withstand pressure gradients and maintain structural integrity. The hollow fiber modules can contain up to 10,000 fibers ranging from 200 to 2500 μm in diameter; The main advantage of hollow fiber modules is the very large surface area within an enclosed volume, increasing the efficiency of the separation process.

Jacqueline Rose, FBA, FRSL (born 1949 in London) academic; Professor of Humanities at the Birkbeck Institute for the Humanities; scholar, and author of over ten books and monographs on psychoanalysis, epistemology, ontology and feminism; critical of Zionism, describing it as "[having] been traumatic for the Jews as well as the Palestinians". Nikolas Rose is a British sociologist and social theorist. He is Distinguished Honorary Professor at the Research School of Social Sciences, in the College of Arts and Social Sciences at the Australian National University and Honorary Professor at the Institute of Advanced Studies at University College London. Steven Rose (born 4 July 1938) neuroscientist, prolific author, social commentator; instrumental in calling for Academic boycott of Israel as long as Israel continues its occupation of the Palestinian Territories, on grounds of Israeli academics' close relationship with Israel Defense Forces; founding members of British Committee for the Universities of Palestine;regular panellist on BBC Radio 4's ethics debating series The Moral Maze. Connie Rosen, education writer (born 1919)in the East End of London; and BBC playwright. Author of The Language of Primary Schoolchildren, co-written with Harold Rosen Penguin, 1973, Penguin Education. Harold Rosen an American-born British educationalist who lived in the UK for most of his life. His particular field was teaching English, and he eventually became an academic at the Institute of Education, part of London University.

== History == The founding meeting for the CSCC was held in Montreal, Quebec on October 17, 1956. Since that time, the membership has grown to several hundred clinical chemists. In 1986 the Canadian Academy of Clinical Biochemistry was established as the academic body of the CSCC to oversee training, certification, accreditation, and professional development of clinical chemists in Canada. A syllabus for post doctoral training in clinical biochemistry was developed and is maintained by the CACB as a guide to program directors and trainees. The CSCC holds an Annual Scientific Congress and Annual General Meeting. The 61st annual CSCC conference was held in San Diego, CA, USA from July 31-August 4, 2017 as a joint meeting with the AACC.

Opioid rotation or opioid switching is the process of changing one opioid to another to improve pain control or reduce unwanted side effects. This technique was introduced in the 1990s to help manage severe chronic pain and improve the opioid response in cancer patients and non-cancer patients. In order to obtain adequate levels of pain relief, patients requiring chronic opioid therapy may require an increase in the original prescribed dose for a number of reasons, including increased pain or a worsening disease state. Over the course of long-term treatment, an increase in dosage cannot be continued indefinitely as unwanted side effects of treatment often become intolerable once a certain dose is reached, even though the pain may still not be properly managed. One strategy used to address this is to switch the patient between different opioid drugs over time, usually every few months. Opioid rotation requires strict monitoring in patients with ongoing levels of high opioid doses for extended periods of time, since long term opioid use can lead to a patient developing tolerance to the analgesic effects of the drug. Patients may also not respond to the first opioid prescribed to them at all, therefore needing to try another opioid to help manage their pain. A patient's specific response and sensitivity to opioids include many factors that include physiology, genetics and pharmacodynamic parameters, which together determine the amount of pain control and tolerance of a particular opioid.

Sources: en.wikipedia.org

Frequently asked questions